Enliven Therapeutics, Inc.

ELVNSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1672619

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$80.8M	$64.6M	$31.0M	$38.4M	$32.2M
Operating Expenses	$104.6M	$83.5M	$38.8M	$51.4M	$41.7M
Operating Income (Loss)	-$104.6M	-$83.5M	-$38.8M	-$51.4M	-$41.7M
Nonoperating Income (Expense)	$15.5M	$11.9M	$1.1M	$58.0K	$338.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	-$51.4M	—
Income Tax Expense (Benefit)	$232.0K	$0.00	$0.00	$88.0K	—
Net Income (Loss) Attributable to Parent	-$89.0M	-$71.6M	-$37.7M	-$51.4M	-$41.4M
Earnings Per Share, Basic	-$1.89	-$2.01	-$12.05	-$2.37	—
Earnings Per Share, Diluted	-$1.89	-$2.01	-$12.05	-$2.37	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$325.8M	$271.9M	$83.3M	$93.6M	$90.8M
Assets, Current	$318.1M	$266.2M	$77.8M	$92.7M	$90.4M
Cash and Cash Equivalents, at Carrying Value	$124.1M	$100.1M	$75.5M	$48.3M	$47.7M
Liabilities	$15.9M	$26.0M	$10.4M	$7.6M	$6.4M
Liabilities, Current	$15.9M	$25.9M	$9.7M	$7.2M	$6.2M
Accounts Payable, Current	$1.3M	$532.0K	$3.4M	$2.4M	$2.0M
Stockholders' Equity Attributable to Parent	$245.9M	-$76.8M	-$42.9M	$84.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$73.2M	-$61.3M	-$32.1M	-$46.8M	-$37.4M
Net Cash Provided by (Used in) Investing Activities	-$36.0M	-$148.4M	-$612.0K	-$1.6M	-$16.7M
Net Cash Provided by (Used in) Financing Activities	$133.2M	$234.3M	-$1.8M	$49.1M	$96.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)